Proactive Investors - Run By Investors For Investors

OptiBiotix Health hails scientific and commercial progress

"The company believes it is making strong scientific and commercial progress across all its technology and product platforms," said the company's CEO, Stephen O'Hara
Good and bad cholesterol
More products are entering the commercialisation phase.

OptiBiotix Health PLC (LON:OPTI) is close to completing the processes required to meet US regulatory compliance standards for the manufacture of its LPLDL strain.

OptiBiotix, which is responsible for the manufacture of the cholesterol-reducing Lactobacillus Plantarum LPLDL strain, said it has been working with its manufacturing partner to invest in and develop the necessary pharmaceutical processes, supporting documentation, and production batches to confirm regulatory compliance. It anticipates this work will be completed by the end of July 2019 with certification following shortly afterwards.

READ OptiBiotix’s LPLDL cholesterol-reducing strain to be used in vascular health product

In a scientific and commercial update, the life sciences firm noted that receiving certification would trigger a second milestone payment and allow it to market LPLDL as a product manufactured to pharmaceutical standards, thus opening up further opportunities with pharmaceutical companies.

The company is developing a number of products based on SweetBiotix, the company’s low-calorie alternative to sugar, and these are now undergoing manufacturing scale-up with a US corporate partner.

On the commercial side, the company said it continued to see revenue growth in early 2019 and is expecting further growth in the second half of the year, while various product launches are scheduled to occur in 2020.

“With current products winning awards for their science and product innovation and growing deal flow across international markets, the company is continuing to grow revenue streams across a broad deal pipeline,” declared Stephen O’Hara, the chief executive officer of OptiBiotix.

“If most of these partners deliver on their forecasts, revenues will continue to grow in the months and years ahead. We are particularly pleased that, as the value of our brands increase internationally, we are seeing increased retail interest and a number of our larger corporate partners committing to product launches," he added.

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use